Xenoport, Inc.

Arbor Pharmaceuticals, LLC

Biomea Fusion, Inc.

Mark A. Gallop

Suresh K. Manthati

Thu Phan

Maria Ludwikow

Stephen P. Raillard

Xuedong Dai

Fenmei Yao

Randall A. Scheuerman

Ge Peng

Seema Bhat

Mark A Gallop

Maria J Ludwikow

Suresh Kumar Manthati

Randall A Scheuerman

Stephen P Raillard

Seema Rani Bhat

Feng Xu

Usha Dilip

Thorsten A Kirschberg

Nan-Horng Lin

David Juergen Wustrow

Thomas Butler

Xiaodong Wang

Ravindra B Upasani

Yongli Su

James T Palmer

David Sperandio

Solomon B Ungashe

Amna Trinity-Turjuman Adam

Neil Howard Squires

Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Pyrazine compounds as inhibitors of FLT3

The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof

Gamma-amino-butyric acid derivatives that are GABAreceptor ligands, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives and pharmaceutical compositions thereof for treating diseases are disclosed.

[object Object]

Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders such as mild cognitive impairment, cognitive impairment associated with Alzheimer's disease Alzheimer's disease, depression, anxiety, and epilepsy are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, which are suitable for oral administration and sustained release oral dosage forms are also disclosed.

Growing community of inventors

Fremont, CA, United States of America

Thu Phan